Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPKI0N)

• Drug Name: EBIO Drug Info
• Synonyms: 10045-45-1; 1-Ethyl-2-benzimidazolinone; 1-EBIO; 1-ethyl-1H-benzo[d]imidazol-2(3H)-one; 1-Ethylbenzimidazolinone; 1-Ethylbenzimidazolin-2-one; 1-ethyl-1,3-dihydro-2h-benzimidazol-2-one; 2H-Benzimidazol-2-one, 1-ethyl-1,3-dihydro-; 1-Ethyl-Benzimidazolinone; UNII-M82W79SS4W; 3-ethyl-1H-benzimidazol-2-one; EINECS 233-148-1; CHEMBL452887; M82W79SS4W; CHEBI:34076; CXUCKELNYMZTRT-UHFFFAOYSA-N; 1-ethyl-2,3-dihydro-1H-1,3-benzodiazol-2-one; 1-EB10; EBIO; 1-ethyl-1,3-dihydrobenzimidazol-2-one; Tocris-1041; AC1Q2ZX3; AC1Q2ZX4

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 82320
  ChEBI ID: CHEBI:34076
  CAS Number: CAS 10045-45-1
  TTD Drug ID: DMPKI0N

Molecule-Related Drug Atlas

Drug(s) Targeting Calcium-activated potassium channel KCa2.3 (KCNN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
dequalinium	DMXM19W	Myelopathy	8B42	Clinical trial	[4]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[2]
UCL1684	DMZNJFU	Discovery agent	N.A.	Investigative	[5]
DC-EBIO	DM2T5OV	Discovery agent	N.A.	Investigative	[6]
UCL1848	DM2CN0A	Discovery agent	N.A.	Investigative	[5]
apamin	DMYNBK5	Discovery agent	N.A.	Investigative	[5]
CyPPA	DM64L9I	Discovery agent	N.A.	Investigative	[7]

Drug(s) Targeting Calcium-activated potassium channel KCa2.1 (KCNN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
dequalinium	DMXM19W	Myelopathy	8B42	Clinical trial	[8]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[2]
UCL1684	DMZNJFU	Discovery agent	N.A.	Investigative	[2]
UCL1848	DM2CN0A	Discovery agent	N.A.	Investigative	[9]
apamin	DMYNBK5	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Calcium-activated potassium channel KCa3.1 (KCNN4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ICA-17043	DMRFY7I	Alzheimer disease	8A20	Phase 2	[10]
ASP0819	DM6HJ3V	Fibromyalgia	MG30.01	Phase 2	[11]
DC-EBIO	DM2T5OV	Discovery agent	N.A.	Investigative	[12]
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole	DMQEJVU	Conjunctival fibrosis	9A61.3	Investigative	[13]
SKA-121	DMBL7YN	Discovery agent	N.A.	Investigative	[14]
PMID15603962Crac-16	DMN5LZQ	Discovery agent	N.A.	Investigative	[15]
SKA-31	DMX34F1	Discovery agent	N.A.	Investigative	[16]

Drug(s) Targeting Calcium-activated potassium channel KCa2.2 (KCNN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
dequalinium	DMXM19W	Myelopathy	8B42	Clinical trial	[17]
zoxazolamine	DM70TKB	Multiple myeloma	2A83	Terminated	[18]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[2]
UCL1684	DMZNJFU	Discovery agent	N.A.	Investigative	[8]
DC-EBIO	DM2T5OV	Discovery agent	N.A.	Investigative	[19]
UCL1848	DM2CN0A	Discovery agent	N.A.	Investigative	[20]
apamin	DMYNBK5	Discovery agent	N.A.	Investigative	[21]
CyPPA	DM64L9I	Discovery agent	N.A.	Investigative	[7]

Drug(s) Affected By Lysozyme C (LYZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[22]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[23]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[24]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[25]
Glibenclamide	DM8JXPZ	Diabetic complication	5A2Y	Approved	[3]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[27]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[29]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[30]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium-activated potassium channel KCa2.1 (KCNN1)	TT9R6BE	KCNN1_HUMAN	Activator	[2]
Calcium-activated potassium channel KCa2.2 (KCNN2)	TT2T5M0	KCNN2_HUMAN	Activator	[2]
Calcium-activated potassium channel KCa2.3 (KCNN3)	TT9JH25	KCNN3_HUMAN	Activator	[2]
Calcium-activated potassium channel KCa3.1 (KCNN4)	TT7M9I6	KCNN4_HUMAN	Activator	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Lysozyme C (LYZ)	OTD7H0G6	LYSC_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2314).
• [2] Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
• [3] Regulation of antiprotease and antimicrobial protein secretion by airway submucosal gland serous cells. J Biol Chem. 2004 Sep 10;279(37):38854-60. doi: 10.1074/jbc.M407077200. Epub 2004 Jul 2.
• [4] Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines. Neuropharmacology. 2001 May;40(6):772-83.
• [5] SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones. J Physiol. 2001 Sep 1;535(Pt 2):323-34.
• [6] Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007;14(13):1437-57.
• [7] Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br J Pharmacol. 2007 Jul;151(5):655-65.
• [8] Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol. 2000 Mar;129(5):991-9.
• [9] The pharmacology of hSK1 Ca2+-activated K+ channels expressed in mammalian cell lines. Br J Pharmacol. 2000 Feb;129(4):627-30.
• [10] Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.Expert Opin Investig Drugs.2009 Feb;18(2):231-9.
• [11] Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. J Pain Res. 2020 Dec 10;13:3355-3369.
• [12] Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2001 Feb;296(2):600-11.
• [13] Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 2003 Sep 2;108(9):1119-25.
• [14] New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Mol Pharmacol. 2014 Sep;86(3):342-57.
• [15] IKCa-channel blockers. Part 2: discovery of cyclohexadienes. Bioorg Med Chem Lett. 2005 Jan 17;15(2):401-4.
• [16] Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol. 2009 Feb;75(2):281-95.
• [17] Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds. Eur J Pharmacol. 2000 Jul 28;401(1):1-7.
• [18] Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds. J Pharmacol Exp Ther. 2001 Mar;296(3):683-9.
• [19] Specific enhancement of SK channel activity selectively potentiates the afterhyperpolarizing current I(AHP) and modulates the firing properties of ... J Biol Chem. 2005 Dec 16;280(50):41404-11.
• [20] Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J Biol Chem. 2001 Apr 13;276(15):12249-56.
• [21] SK2 encodes the apamin-sensitive Ca(2+)-activated K(+) channels in the human leukemic T cell line, Jurkat. FEBS Lett. 2000 Mar 10;469(2-3):196-202.
• [22] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [23] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [24] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [25] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [26] DNA microarray analysis of changes in gene expression induced by 1,25-dihydroxyvitamin D3 in human promyelocytic leukemia HL-60 cells. Biomed Res. 2006 Jun;27(3):99-109. doi: 10.2220/biomedres.27.99.
• [27] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [28] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [29] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [30] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.